About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron
Rhea-AI Summary
UTime (NASDAQ: WTO) has announced its collaboration on Circul VS, a continuous blood pressure measurement technology system developed with Dr. Ehud Baron. The system includes a BPwatch, Ring, and Smart Cradle, integrated into a cloud-based network. Circul VS utilizes ultrasound sensing technology and intelligent algorithms to provide real-time blood pressure waveform data with high accuracy.
The system has undergone clinical trials in partner hospitals, receiving positive feedback for its performance in non-invasive monitoring. Circul VS is designed for various applications, including hypertension screening, long-term management, and acute monitoring in hospital settings. UTime and Dr. Baron plan to further refine the technology for use in ICUs and other medical environments.
Positive
- Development of innovative continuous blood pressure monitoring system
- Utilization of advanced ultrasound sensing technology and intelligent algorithms
- Positive feedback from clinical trials in partner hospitals
- Versatility in application scenarios (screening, management, and acute monitoring)
- Potential for widespread use in ICUs and other medical settings
Negative
- None.
News Market Reaction
On the day this news was published, WTO declined 4.55%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Circul VS features the BPwatch, Ring, and Smart Cradle, integrated into a sophisticated cloud-based network and service system. Unlike other systems on the market, Circul VS focuses on capturing rapid blood pressure fluctuations caused by changes in endothelial function and vascular tone—critical factors often neglected by competitors.
Utilizing state-of-the-art ultrasound sensing technology and intelligent algorithms, Circul VS provides continuous, real-time blood pressure waveform data with exceptional accuracy. This innovative technology is the result of comprehensive market research and extensive clinical studies.
As part of this strategic collaboration, UTime has harnessed expertise in biomedical engineering and electronic technology to ensure the Circul VS system is not only precise but also stable and reliable in diverse clinical settings.
Having undergone clinical trials in multiple partner hospitals, Circul VS has garnered positive feedback for its outstanding performance in the non-invasive monitoring space, offering systolic and diastolic pressure readings with accuracy approaching that of invasive techniques.
During its development, Circul VS was tailored to meet the needs of different application scenarios—including hypertension screening for healthy individuals, long-term management for diagnosed hypertension patients, and acute monitoring for hospitalized patients. This adaptability ensures it meets the specific demands of various clinical environments.
The launch of Circul VS marks a pivotal advancement in blood pressure monitoring technology. Together with Dr. Ehud Baron, UTime plans to continue refining this technology, aiming to enhance its intelligence and accuracy for widespread use in ICUs and other medical settings, ultimately improving patient care and quality of life.
About UTime Limited
UTime Ltd., established in 2008, provides cost-effective mobile devices to consumers globally and to helping low-income individuals from established markets, including the United States and emerging markets such as India and other countries in South Asia and Africa have better access to updated mobile technology. Since 2024, UTime has been committed to transforming health and wellness through innovative medical wearable technologies. By leveraging cutting-edge research and strategic partnerships, UTime aims to provide effective solutions for disease prevention and health management on a global scale. For more information, visit the Company's website at http://www.utimeworld.com/.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the ability of the Company to regain compliance with Nasdaq continued listing requirements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the "Risk Factors" section of the Annual Report in Form 20-F filed with the SEC on July 30, 2024. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
Eaky Tan
eaky@westock.com
View original content:https://www.prnewswire.com/news-releases/about-circul-vs-a-core-continuous-blood-pressure-measurement-technology-system-developed-in-partnership-with-dr-ehud-baron-302230345.html
SOURCE UTime Limited
FAQ
What is Circul VS and how does it work?
What components make up the Circul VS system?
Has Circul VS undergone clinical trials?
What are the potential applications for Circul VS?
